article thumbnail

An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine

Bio Pharma Dive

Rampart Biosciences closed a Series A round that will fund its goal to develop more potent DNA-based medicines that avoid immune responses.

DNA 263
article thumbnail

Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique

BioSpace

The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective genes without breaking DNA double helix strands.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intellia, ReCode partner on genetic medicines for cystic fibrosis

Bio Pharma Dive

The partnership will use Intellia's "DNA writing” technology, and initially focus on people with the lung disease who have limited or no available treatment options.

Genetics 171
article thumbnail

Hopewell Therapeutics raises funds for genomic medicines development

Pharmaceutical Technology

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130
article thumbnail

Which Career Combines DNA Technology and Medicine?

BioSpace

Which career combines DNA technology and medicine? The answer to that question is medical genetics and the job titles involved around it. Some of the examples are clinical geneticists, genetics counselors and clinical laboratory geneticists.

DNA 64
article thumbnail

Unlocking the potential of synthetic DNA 

Drug Discovery World

Raquel Sanches-Kuiper , Vice President of Science and Applications at Evonetix, and Clare Whitewoods , Marketing Communications Manager at Evonetix, look at the benefits synthetic DNA brings to pharmaceutical development.

DNA 69
article thumbnail

Moderna and Generation Bio partner for genetic medicines development

Pharmaceutical Technology

Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. Moderna’s biological and technical expertise will be combined with core technologies of the non-viral genetic medicine platform from Generation Bio.

Genetics 130